文献速递哮喘

全生命周期中的T2高型哮喘表型

T2-high asthma phenotypes across lifespan.
PubMed 文献 · Eur Respir J · 2022-09-29

在ALLIANCE多中心队列中随访1125名参与者(776例哮喘,349例对照),基于血嗜酸性粒细胞计数和特异性IgE定义四种互斥表型,发现T2高型哮喘存在于所有年龄段,儿童期可持续至2年随访,成人T2高型与儿童期起病相关。

要点

  • 基于血嗜酸性粒细胞和特异性IgE可定义T2高型哮喘表型。
  • T2高型哮喘存在于所有年龄段并可长期持续。
  • T2高型哮喘特征为特异性IgE过度产生,学龄期起IL-5产生增加。

核心结论

  • 使用易获取的生物标志物可在所有年龄段识别T2高型哮喘患者,该表型特征鲜明,患者可能从生物制剂治疗中获益,甚至可更早使用。

研究设计与样本

  • 多中心临床ALLIANCE队列招募1125名参与者(776例哮喘,349例对照),随访2年(成人1年),基线及随访时进行全面临床特征评估,包括问卷、血细胞分类计数、过敏测试、肺功能及成人痰诱导。

主要发现

  • 基于血嗜酸性粒细胞计数和过敏原特异性血清IgE抗体,患者被分为四种互斥表型:仅特应性、仅嗜酸性粒细胞增多、T2高型(嗜酸性粒细胞增多+特应性)和T2低型(两者均无)。
  • T2高型表型存在于所有年龄段,甚至在非常年幼的儿童中,且大部分在2年随访后仍持续。
  • 成人T2高型哮喘与儿童期起病相关,提示该哮喘表型起源较早。
  • 儿童和成人T2高型表型均以针对过敏原的特异性IgE过度产生为特征(p<0.0001),且从学龄期起,全血抗CD3/CD28刺激后IL-5产生增加。

临床怎么用

  • 临床可用血嗜酸性粒细胞计数和过敏原特异性IgE识别各年龄段的T2高型哮喘患者,考虑生物制剂治疗可能使年轻患者获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children. OBJECTIVES: To define T2-high asthma with easily accessible biomarkers and compare resulting phenotypes across all ages. METHODS: In the multicentre clinical All Age Asthma Cohort (ALLIANCE), 1125 participants (n=776 asthmatics, n=349 controls) were recruited and followed for 2 years (1 year in adults). Extensive clinical characterisation (questionnaires, blood differential count, allergy testing, lung function and sputum induction (in adults)) was performed at baseline and follow-ups. Interleukin (IL)-4, IL-5 and IL-13 were measured after stimulation of whole blood with lipopolysaccharide (LPS) or anti-CD3/CD28. MEASUREMENTS AND MAIN RESULTS: Based on blood eosinophil counts and allergen-specific serum IgE antibodies, patients were categorised into four mutually exclusive phenotypes: "atopy-only", "eosinophils-only", "T2-high" (eosinophilia + atopy) and "T2-low" (neither eosinophilia nor atopy). The T2-high phenotype was found across all ages, even in very young children in whom it persisted to a large degree even after 2 years of follow-up. T2-high asthma in adults was associated with childhood onset, suggesting early origins of this asthma phenotype. In both children and adults, the T2-high phenotype was characterised by excessive production of specific IgE to allergens (p<0.0001) and, from school age onwards, by increased production of IL-5 after anti-CD3/CD28 stimulation of whole blood. CONCLUSIONS: Using easily accessible biomarkers, patients with T2-high asthma can be identified across all ages delineating a distinct phenotype. These patients may benefit from therapy with biologicals even at a younger age.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Maison N, Omony J, Illi S, et al. T2-high asthma phenotypes across lifespan. Eur Respir J. 2022. PMID: 35210326. doi:10.1183/13993003.02288-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。